Acorda Therapeutics has announced an additional late-stage trial of Fampridine-SR for multiple sclerosis. Researchers are working with the FDA to design a new Phase III study of the same or shorter duration as the recently completed trial. That study demonstrated that volunteers taking the drug experienced significantly improved walking speed. Report